Log in
LON:INDV

Indivior Share Forecast, Price & News

GBX 110.11
+5.81 (+5.57 %)
(As of 10/30/2020 05:36 PM ET)
Add
Compare
Today's Range
98.15
Now: GBX 110.11▼
112
50-Day Range
100.61
MA: GBX 111.41▼
122
52-Week Range
32.90
Now: GBX 110.11▼
165.80
Volume10.43 million shs
Average Volume2.45 million shs
Market Capitalization£807.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More
Indivior logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON
Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
Current SymbolLON:INDV
Previous Symbol
CUSIPN/A
CIKN/A
Webindivior.com
Phone+44-1753-217800
Employees915

Debt

Debt-to-Equity Ratio489.66
Current Ratio1.72
Quick Ratio1.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio22.02
P/E GrowthN/A

Sales & Book Value

Annual Sales£634 million
Price / Sales1.27
Cash FlowGBX 127.60 per share
Price / Cash Flow0.86
Book ValueGBX 7.90 per share
Price / Book13.94

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares733,505,024
Market Cap£807.66 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 110.11
+5.81 (+5.57 %)
(As of 10/30/2020 05:36 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Indivior (LON:INDV) Frequently Asked Questions

How has Indivior's stock been impacted by COVID-19 (Coronavirus)?

Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INDV shares have increased by 138.3% and is now trading at GBX 110.11.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Indivior?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Indivior.

What price target have analysts set for INDV?

2 brokers have issued 12 month price targets for Indivior's stock. Their forecasts range from GBX 85 to GBX 200. On average, they anticipate Indivior's stock price to reach GBX 142.50 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for Indivior.

Who are some of Indivior's key competitors?

Some companies that are related to Indivior include Deciphera Pharmaceuticals (DCPH), BTG (BTG), Global Blood Therapeutics (GBT), National Vision (EYE), Inari Medical (NARI), Inspire Medical Systems (INSP), TG Therapeutics (TGTX), The Ensign Group (ENSG), Hypera (HYPMY), Burning Rock Biotech (BNR), Schrödinger (SDGR), Aspen Pharmacare (APNHY), AMN Healthcare Services (AMN), MorphoSys AG (MOR.F) (MOR) and Nektar Therapeutics (NKTR).
View all competitors.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband plc (BBB.L) (BBB), Futura Medical plc (FUM.L) (FUM), Directa Plus (DCTA), Lakehouse plc (LAKE.L) (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote plc (BOY.L) (BOY), (CITY.L) (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

Who are Indivior's key executives?

Indivior's management team includes the following people:
  • Mr. Shaun Thaxter, CEO & Exec. Director
  • Mr. Mark Crossley, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Ingo Elfering, Chief Information & Innovation Officer
  • Mr. Jason Thompson, VP of Investor Relations

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

How do I buy shares of Indivior?

Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 110.11.

How big of a company is Indivior?

Indivior has a market capitalization of £807.66 million and generates £634 million in revenue each year. Indivior employs 915 workers across the globe.

What is Indivior's official website?

The official website for Indivior is indivior.com.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.